WT1 Peptid Vaccination in Carcinomas

Charite University, Berlin, Germany25 enrolled

Overview

In this trial HLA-A2+ patients with WT1 expressing carcinomas are vaccinated with a peptide from the leukemia associated antigen WT1 together with immunological adjuvants KLH as T-helper protein and GM-CSF

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

WT1 Expressing Carcinoma

Interventions

WT1 126-134 peptideBIOLOGICAL

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Metastatic cancer, no standard treatment option * Resected cancer with minimal residual disease, no standard treatment option * WT-1 expression * HLA-A2 Exclusion Criteria: * Concurrent chemotherapy

Locations (1)

Hem&Onc Charité CBF

Berlin, Germany

RECRUITING

Outcomes

Primary Outcomes

Clinical efficacy

Secondary Outcomes

Immune response

Safety

Central Contacts

Carmen Scheibenbogen, MD

CONTACT

+49-30-8445-4576 carmen.scheibenbogen@charite.de

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.